Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was bought at an average cost of $15.34 per share, with a total value of $153,400.00. Following the purchase, the director now owns 106,062 shares in the company, valued at $1,626,991.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Valeant Pharmaceuticals Intl Inc (VRX) opened at $15.79 on Tuesday. Valeant Pharmaceuticals Intl Inc has a 12 month low of $8.31 and a 12 month high of $24.43. The stock has a market cap of $5,510.00, a price-to-earnings ratio of 3.88, a PEG ratio of 0.52 and a beta of -0.28. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 4.25.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals Intl had a net margin of 27.56% and a return on equity of 42.48%. The company had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.18 billion. During the same quarter in the prior year, the company earned $1.26 EPS. The firm’s revenue was down 10.0% on a year-over-year basis. analysts forecast that Valeant Pharmaceuticals Intl Inc will post 3.12 earnings per share for the current fiscal year.
VRX has been the subject of a number of research reports. Zacks Investment Research cut shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research note on Saturday, January 13th. HC Wainwright boosted their price target on shares of Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Wells Fargo & Co reissued a “sell” rating and issued a $9.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, January 16th. TD Securities boosted their price target on shares of Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research note on Friday, January 19th. Seven research analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $18.30.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/03/13/schutter-richard-u-de-purchases-10000-shares-of-valeant-pharmaceuticals-intl-inc-vrx-stock.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.